Latest Insights | BiopharmaTrend

Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

In the latest news, Novo Nordisk has entered a collaboration with Anthropic aimed at speeding the discovery and development of new medicines. An initial project will test Anthropic's Claude Science …

Continue ›››

The Bigger Point Beyond Insilico's Aging Research Milestone

This week Insilico Medicine, an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a …

Continue ›››

The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?

An article published in Nature Biotechnology on 7 September 2026 by Alex Zhavoronkov’s team at Insilico Medicine and collaborators marks an important step forward for the field of drugs targeting …

Continue ›››

What Do the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences?

Last week, Anthropic and OpenAI released new frontier models, specifically, Anthropic shipped Claude Fable 5.1 and a restricted variant called Mythos 5.1, while OpenAI shipped GPT-6 Astra. OpenAI president, Greg …

Continue ›››

Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome

Drug discovery has never had a richer therapeutic toolbox. Antibody-drug conjugates, antisense oligonucleotides, CRISPR therapeutics, RNA medicines, CAR-T cells, PROTACs, and molecular glues have transformed how medicine can manipulate biology. …

Continue ›››

Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms

Biotech treats DNA primarily as a coding material that provides information about disease phenotypes and can serve as a drug target and modality. But beyond the code, DNA is also …

Continue ›››

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent. Everyone is talking about how Anthropic AI lab now designs drugs, hires the AlphaFold Nobel laureate, and ships Claude Science alongside Claude Code. …

Continue ›››

Seven HealthTech Trends In Europe To Watch

I spent last week in Amsterdam, attending HLTH Europe 2026, arguably Europe's flagship healthcare innovation event, hosting more than 5,000 attendees. It is my second HLTH experience, and two additions …

Continue ›››

Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.

The System Is Buckling; Self-Care Is the Solution. Global health systems are buckling under immense pressure. When I attended the World Health Assembly in May, Dr. Wael Ali, board member …

Continue ›››

Is the Future of AI Drug Discovery Hybrid?

Some field notes from the cutting edge of modern bioinformatics (CoFold Summit and Free Energy Workshop, both held recently in Barcelona, Spain). ALSO: several companies to watch in techbio space. …

Continue ›››

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One, a Packaged ADME Service for Early Discovery

Ginkgo Bioworks' (NYSE: DNA) Datapoints arm, Tangible Scientific, and Inductive Bio today launched ADME-One, a single-SKU service that combines a Tier 1 ADME panel, AI-driven human pharmacokinetic projection, and compound …

Continue ›››

Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed... In April, a Toronto-based startup called Biossil came out of stealth with a total of $70 …

Continue ›››